The term “cosmeceutical” was coined in 1984 by dermatologist Albert Kligman to describe products that sit between cosmetics and pharmaceuticals. Forty-two years later, the FDA still does not recognise the category. It does not exist under US law. A product is either a cosmetic or a drug — there is no middle ground, no intermediate classification, no regulatory framework for the $60 billion market of products that claim to modulate epigenetic ageing, clear senescent cells, reverse cellular age, or intervene in biological processes at the molecular level. Japan has “quasi-drugs.” South Korea has “functional cosmetics.” Thailand has “herbal cosmeceuticals.” The world’s largest beauty market has nothing. MoCRA — the Modernization of Cosmetics Regulation Act of 2022 — was meant to begin closing this gap. Its Good Manufacturing Practice rules were due by December 2025. They have been moved to the FDA’s “Long-Term Actions” list, meaning no timeline exists. Meanwhile, products on the same Sephora shelf carry claims ranging from “moisturises skin” to “reverses epigenetic age by eight years in three months.” One has clinical evidence. The other does not. The consumer cannot tell which is which. That is the void.
Analysis via 🪺 6D Foraging Methodology™
Under the Federal Food, Drug, and Cosmetic Act, cosmetics are products intended for cleansing, beautifying, or altering appearance. Drugs are products intended to diagnose, cure, treat, or prevent disease, or to affect the structure or function of the body. A product can be classified as both. But the term “cosmeceutical” has no legal standing. The FDA has stated this explicitly: the term has no meaning under the law.[1]
This binary classification was designed for an era when cosmetics moisturised and drugs treated disease. It was not designed for products that claim to modulate hallmarks of ageing at the cellular level. When a serum claims to reduce epigenetic skin age by eight years in three months using a vitamin C derivative and an antioxidant complex, it is making a structural claim about the human body that sounds more pharmaceutical than cosmetic. Yet it is sold without clinical trials, without FDA pre-market approval, and without the safety substantiation that drug classification would require.[2]
The Congressional Research Service documented the gap in a comprehensive analysis: MoCRA introduced facility registration, product listing, adverse event reporting, and safety substantiation requirements — meaningful upgrades from the essentially self-regulated pre-2022 regime. But it did not create an intermediate product category. It did not define what constitutes adequate safety substantiation. And the GMP regulations that were supposed to provide the enforcement framework have been pushed to the FDA’s long-term agenda without a specified date.[3]
The gap between what products claim and what regulation covers has never been wider. The longevity pivot (UC-135) is accelerating the escalation. Products on consumer shelves now routinely reference epigenetic modulation, cellular senescence intervention, mitochondrial health, and biomarker-validated age reversal. These are biological claims about the structure and function of the human body — the exact language that, under the FD&C Act, would classify a product as a drug. Yet they are sold as cosmetics.[4]
The quality dispersion is the vulnerability. Estée Lauder has a Stanford partnership and peer-reviewed epigenetic research behind its Advanced Night Repair longevity claims (UC-135). Galderma is running FDA-tracked clinical trials for its injectable aesthetics portfolio (UC-134). But on the same shelf, at the same price point, products with zero clinical evidence carry similar longevity language. The consumer cannot distinguish between a formulation backed by Horvath clock validation and one backed by marketing copy. When the Frontiers in Aging paper called for regulatory clarity, it was precisely because the absence of a regulatory category means there is no threshold for which claims require which evidence.[5]
“A product can be a drug, a cosmetic, or a combination of both, but the term ‘cosmeceutical’ has no meaning under the law.”
— US Food and Drug Administration[1]The MoCRA implementation timeline reveals the regulatory lag. The Act was signed in December 2022. Facility registration and product listing deadlines passed in 2024. Safety substantiation requirements are now active — but without defined standards. The GMP proposed rulemaking was due by December 2024; the final rule by December 2025. Both are now on the FDA’s “Long-Term Actions” list. Separately, the FDA’s mandated assessment of PFAS in cosmetics was due by December 2025 — while states including California, Washington, Colorado, and Maryland have already implemented their own PFAS bans, creating a patchwork of state-level regulation in the absence of federal action.[6][7]
This is an at-risk cascade originating in D4 (Regulatory). The regulatory void IS the risk. The absence of a cosmeceutical category means that products making increasingly clinical claims operate without the regulatory infrastructure that exists for actual drugs. This is not a compliance problem — companies are not breaking laws. It is a structural gap: the laws do not cover the products that exist.
D4 cascades into D3 (Revenue), D1 (Customer), and D6 (Operational). D3 because the $60 billion cosmeceutical market is built on claims that could be challenged if regulation catches up — companies making longevity claims without clinical evidence face reformulation costs, relabelling requirements, or market withdrawal. D1 is the at-risk dimension because consumers are making health decisions based on cosmetic-grade evidence. When 86% of GLP-1 patients express interest in regenerative treatments (UC-135), many will encounter products with longevity claims backed by nothing more than marketing copy. A single adverse event from a “longevity” product could trigger the consumer trust cascade that the entire longevity pivot depends on. D6 because manufacturers are adapting to MoCRA baseline requirements while simultaneously incorporating biotech ingredients without pharmaceutical-grade quality controls.
At L2, D5 (Quality) activates through the evidence dispersion — the gap between Stanford-partnered epigenetic platforms and TikTok-viral products using the same vocabulary is a quality fault line that the regulatory void permits to exist. D2 (Employee) is lowest at 42 — compliance officers and regulatory affairs teams are affected but the workforce dimension is not yet under acute pressure.
UC-068 mapped AI entering healthcare without adequate guardrails — the same structural pattern as beauty entering clinical territory without regulatory infrastructure. In both cases, the technology (or product) outpaces the governance framework. In both cases, the consumer is the exposure point. UC-068’s D1 origin (patient trust) mirrors UC-136’s D1 at-risk status (consumer trust). The difference: in healthcare AI, the regulatory response is forming (EU AI Act, HIPAA extensions). In beauty-as-medicine, the regulatory response is absent. → Read UC-068: The Bedside Manner
UC-025 mapped the IP vacuum in fashion — no copyright protection for clothing design, forcing brands to build identity moats as substitute protection. The regulatory void in beauty is structurally identical: no regulatory category for cosmeceuticals, forcing brands with real clinical evidence to compete in the same unregulated market as brands with none. The same dimension (D4) creates the same structural dynamic in a different sector: when law does not protect quality, the market does not reward it. → Read UC-025: The Identity Moat
-- The Regulatory Void: 6D At-Risk Cascade
FORAGE regulatory_void
WHERE fda_cosmeceutical_category = false
AND cosmeceutical_market_value >= 60e9
AND mocra_gmp_delayed = true
AND clinical_claims_without_trials = true
AND international_intermediate_categories >= 3
AND longevity_claims_escalating = true
ACROSS D4, D3, D1, D6, D5, D2
DEPTH 3
SURFACE regulatory_void
DRIFT regulatory_void
METHODOLOGY 85 -- FDA's own guidance page confirms cosmeceuticals have "no meaning under the law." Congressional Research Service R47826 documents MoCRA implementation gaps. UL Prospector tracks GMP delay to "Long-Term Actions." Frontiers in Aging peer-reviewed paper calls out regulatory gap. Japan/Korea/Thailand intermediate categories confirmed via multiple regulatory sources. State-level PFAS bans documented across California, Washington, Colorado, Maryland.
PERFORMANCE 35 -- The void has existed for 42 years. MoCRA was the first meaningful reform since 1938. But its strongest provisions (GMP) are delayed. No adverse event has yet triggered regulatory acceleration. The longevity claims escalation is recent (2025-2026). Whether this generates regulatory action or continues unchecked is genuinely uncertain. The risk is structural and growing, but the trigger event has not occurred.
FETCH regulatory_void
THRESHOLD 1000
ON EXECUTE CHIRP at-risk "The FDA does not recognise cosmeceuticals. A $60B market making clinical claims operates in a regulatory void. D4 origin: the absence of regulation IS the risk. MoCRA's GMP rules delayed indefinitely. Products claiming epigenetic reversal, cellular longevity, and senescent cell clearance sold as cosmetics without clinical trials. AT RISK: D1 (consumers making health decisions on cosmetic-grade evidence) and D4 (the gap widening as longevity claims escalate). Japan, Korea, and Thailand have intermediate categories. The US and EU do not. A single adverse event from a 'longevity' product could trigger the regulatory cascade the industry has avoided for 42 years. UC-136 maps the risk that UC-134's bridge and UC-135's pivot are generating."
SURFACE analysis AS jsonRuntime: @stratiqx/cal-runtime · Spec: cal.cormorantforaging.dev · DOI: 10.5281/zenodo.18905193
For 42 years, the cosmeceutical market has been governed by a non-category. The FDA’s position is that existing classifications (cosmetic, drug, or both) are sufficient. The market’s position is that $60 billion in products occupy a space between the two that neither classification adequately addresses. The absence of a regulatory category is itself a regulatory decision: it means the industry self-polices, consumers self-assess, and the quality floor is set by market forces rather than safety standards. This worked when products moisturised. It does not work when products claim to reverse epigenetic age.
Japan, South Korea, and Thailand have created intermediate categories that bridge cosmetics and pharmaceuticals. These frameworks require varying degrees of efficacy evidence, safety documentation, and government approval for health-adjacent claims. They are not perfect, but they demonstrate that the binary cosmetic/drug classification is not the only option. If the US and EU eventually create intermediate categories, the Asian precedents will shape the structure. Companies already compliant with quasi-drug or functional cosmetics standards in Asia will have a regulatory head start in the West.
The regulatory void has persisted because no forcing function has materialised. MoCRA was the legislative response to contamination scandals and asbestos in talc. The longevity claims escalation has not yet produced a consumer safety crisis. But the GLP-1 demand wave (UC-134) is sending millions of patients toward products with unverified longevity claims. The probability of an adverse event — a consumer harmed by a product making clinical claims without clinical evidence — increases with each new consumer entering the category. The trigger event is not a question of if but when, and whether it is a single incident or a systemic pattern.
In a regulated market, the minimum quality threshold is set by law. In the regulatory void, the quality threshold is set by evidence. Companies with clinical trials (Galderma), epigenetic research platforms (Estée Lauder), and peer-reviewed frameworks are building moats that cannot be replicated by marketing copy. When regulation eventually arrives — triggered by an adverse event, an Asian-precedent adoption, or EU expansion — these companies will already be compliant. The regulatory void is a temporary condition. The evidence moat is a permanent competitive advantage.
The 6D Foraging Methodology™ reads what others call “light-touch regulation” and finds the structural vulnerability underneath. One conversation. We’ll tell you if the six-dimensional view adds something new.